P
HRTX icon

&Partners’s Heron Therapeutics HRTX Stock Holding History

&Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.3K Buy
+22,927
New +$26.6K ﹤0.01% 2382

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

&Partners's HRTX Position: Q1 2026 in Review

&Partners opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 22,927 shares worth $18.3K. The stake represents ﹤0.01% of the portfolio and ranks #2382 among its holdings.

167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • &Partners held 22,927 shares of Heron Therapeutics worth $18.3K as of Q1 2026.
  • Heron Therapeutics was a new &Partners position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2382 holding.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.